-
New Progress of Potential "Specific Drugs" for COVID-19: Masitinib + S2H97
Industry Data
ChuxinAugust 02, 2021
Since the outbreak of COVID-19 at the end of 2019, it has spread all over the world. Up to now, more than 190 million confirmed cases of COVID-19 have been reported worldwide, and more than 4.11 million patients have died, causing great disasters.
-
Cocktail COVID-19 Neutralizing Antibody was Officially Approved in Japan to Build a Second Line of Defense
Industry Data
XiaoyaowanAugust 02, 2021
Recently, Ronapreve, a product of Roche Pharmaceuticals, was approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of mild to moderate COVID-19 patients by intravenous infusion.
-
Rec-Biotechnology Went to Hong Kong IPO, Aiming at the HPV Vaccine Market Worth Tens of Billions and Creating an Innovation Engine of Comprehensive Vaccine
Industry Data
YefenghongAugust 02, 2021
On July 16, Rec-Biotechnology submitted its prospectus to HKEX and was accepted. Rec-Biotechnology is an innovative vaccine company, and its core product, Human Papillomavirus 9-valent Vaccine, Recombinant, is in Phase III clinical trial stage.
-
Chinese BTK Inhibitor Orelabrutinib Has Gone Global. What Other Drugs Have Been Ok'd Overseas in 2021
Industry Data
DopineJuly 26, 2021
On July 13, InnoCare Pharma and Biogen made joint announcement that they have entered into an agreement on the license and cooperation of the BTK inhibitor Orelabrutinib.
-
Covid-19 Oral Medicine -- a Link to be focused on Against Epidemic
Industry Data
ChuxinJuly 26, 2021
In the wake of the outbreak of the COVID-19, the globally cumulative infected population has capped 100 million, which poses a huge impact on human activities.
-
Sun Pharma's SMO inhibitor Sonidegib at $175m about to be granted in China
Industry Data
DopineJuly 26, 2021
On July 13th, the status of Class 5.1 import application for "Sonidegib Phosphate Capsules" by Sun Pharmaceuticals/Jemincare progressed to "under review" at the NMPA, and it is foreseen that it will be duly approved soon.
-
Release of a Novel Domestic Class 1 Anti-HIV drug May Reshape the Market
Industry Data
YefenghongJuly 20, 2021
On June 25, Aidea Pharmaceutical obtained approval for the marketing application of a new Class 1 drug ACC007 for the treatment of HIV-1 infection submitted by CDE of NMPA of China.
-
Pharmaceutical Companies Back to the Blue Ocean of AD in the Wake of Aduhelm's Approval
Industry Data
YefenghongJuly 20, 2021
On June 8, the FDA issued an accelerated approval to Biogen/Eisai's powdered protein antibody Aduhelm (generic name aducanumab) for the treatment of Alzheimer's disease (AD).
-
Good News in the Anti-AβAntibodies Field, Two Drugs were Successively Granted Breakthrough Drug Qualification by the FDA
Industry Data
PharmaSourcesJuly 13, 2021
Two AD drugs have been granted BTD by the FDA recently, namely Eisai/Biogen's Lecanemab (BAN2401) and Eli Lilly's Donanemab.
-
Another Giant Entering, the TIGIT Antibody Market is Highly Competitive
Industry Data
DopineJuly 09, 2021
GlaxoSmithKline (GSK) and iteos Therapeutics have announced a collaboration to jointly develop and commercialize EOS-448. EOS-448 is an anti-TIGIT monoclonal antibody, which is in the phase I development.
Since the outbreak of COVID-19 at the end of 2019, it has spread all over the world. Up to now, more than 190 million confirmed cases of COVID-19 have been reported worldwide, and more than 4.11 million patients have died, causing great disasters.
Recently, Ronapreve, a product of Roche Pharmaceuticals, was approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of mild to moderate COVID-19 patients by intravenous infusion.
On July 16, Rec-Biotechnology submitted its prospectus to HKEX and was accepted. Rec-Biotechnology is an innovative vaccine company, and its core product, Human Papillomavirus 9-valent Vaccine, Recombinant, is in Phase III clinical trial stage.
On July 13, InnoCare Pharma and Biogen made joint announcement that they have entered into an agreement on the license and cooperation of the BTK inhibitor Orelabrutinib.
In the wake of the outbreak of the COVID-19, the globally cumulative infected population has capped 100 million, which poses a huge impact on human activities.
On July 13th, the status of Class 5.1 import application for "Sonidegib Phosphate Capsules" by Sun Pharmaceuticals/Jemincare progressed to "under review" at the NMPA, and it is foreseen that it will be duly approved soon.
On June 25, Aidea Pharmaceutical obtained approval for the marketing application of a new Class 1 drug ACC007 for the treatment of HIV-1 infection submitted by CDE of NMPA of China.
On June 8, the FDA issued an accelerated approval to Biogen/Eisai's powdered protein antibody Aduhelm (generic name aducanumab) for the treatment of Alzheimer's disease (AD).
Two AD drugs have been granted BTD by the FDA recently, namely Eisai/Biogen's Lecanemab (BAN2401) and Eli Lilly's Donanemab.
GlaxoSmithKline (GSK) and iteos Therapeutics have announced a collaboration to jointly develop and commercialize EOS-448. EOS-448 is an anti-TIGIT monoclonal antibody, which is in the phase I development.
Pharma Sources Insight 08/2021